Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754570 | 0.83 | HRH3 (0.60) | HRH3MAPT | |
| SCHEMBL20846483 | 0.81 | HRH3 (0.42) | HRH3POLBLMNA | |
| SCHEMBL25141644 | 0.79 | ALDH1A1 (0.41) | HRH3POLBMAPT | |
| SCHEMBL25754621 | 0.78 | HRH3 (0.33) | HRH3 | |
| SCHEMBL17552087 | 0.77 | POLB (0.57) | HRH3POLBKMT2A | |
| SCHEMBL14083741 | 0.77 | ALDH1A1 (0.43) | HRH3 | |
| SCHEMBL25754652 | 0.77 | CARM1 (0.42) | HRH3MAPTCARM1PRMT6PRMT8 | |
| SCHEMBL25754568 | 0.77 | HRH3 (0.43) | HRH3MAPT | |
| SCHEMBL25754561 | 0.77 | SIGMAR1 (0.41) | — | |
| SCHEMBL967849 | 0.76 | HRH3 (0.48) | HRH3POLBKMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186245-B1 | MAPK INHIBITORS | EverBrilliant Pharma Pty Ltd (AU) | 2021-06-23 | — | — | EP | disclosed |
| US-20170266173-A1 | MAPK INHIBITORS | EVERBRILLIANT PHARMA PTY LTD. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20170266173-A1 | MAPK INHIBITORS | EVERBRILLIANT PHARMA PTY LTD. (AU) | 2017-09-21 | — | — | US | disclosed |
| WO-2016029263-A1 | MAPK INHIBITORS | WANG BING HUI (AU) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266173-A1 | MAPK INHIBITORS | MAPK1, MAPK4, MAPK3 | HRH3 3233/4885POLB 3419/4885KMT2A 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.